NasdaqGS:ACAD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$3.4b

Last Updated

2021/07/27 02:12 UTC

Data Sources

Company Financials +

Executive Summary

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has ACADIA Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ACAD's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

-8.3%

ACAD

0.6%

US Biotechs

3.3%

US Market


1 Year Return

-52.0%

ACAD

19.1%

US Biotechs

37.8%

US Market

Return vs Industry: ACAD underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: ACAD underperformed the US Market which returned 39.1% over the past year.


Shareholder returns

ACADIndustryMarket
7 Day-8.3%0.6%3.3%
30 Day-18.6%-0.1%1.1%
90 Day1.1%0.7%2.9%
1 Year-52.0%-52.0%20.8%19.1%39.9%37.8%
3 Year43.8%43.8%26.1%19.9%65.8%55.4%
5 Year-42.8%-42.8%43.9%32.5%124.3%99.4%

Long-Term Price Volatility Vs. Market

How volatile is ACADIA Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ACADIA Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACAD ($21.29) is trading below our estimate of fair value ($150.66)

Significantly Below Fair Value: ACAD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACAD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ACAD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACAD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACAD is overvalued based on its PB Ratio (5.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is ACADIA Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

77.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ACAD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACAD's is expected to become profitable in the next 3 years.

Revenue vs Market: ACAD's revenue (29% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: ACAD's revenue (29% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACAD's Return on Equity is forecast to be low in 3 years time (10.3%).


Past Performance

How has ACADIA Pharmaceuticals performed over the past 5 years?

-0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACAD is currently unprofitable.

Growing Profit Margin: ACAD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACAD is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare ACAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: ACAD has a negative Return on Equity (-44.71%), as it is currently unprofitable.


Financial Health

How is ACADIA Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ACAD's short term assets ($674.0M) exceed its short term liabilities ($109.4M).

Long Term Liabilities: ACAD's short term assets ($674.0M) exceed its long term liabilities ($64.2M).


Debt to Equity History and Analysis

Debt Level: ACAD is debt free.

Reducing Debt: ACAD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACAD has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACAD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACAD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Steve Davis (60 yo)

5.83yrs

Tenure

US$7,763,187

Compensation

Mr. Stephen R. Davis, also known as Steve, J.D., serves as the Director at Heron Therapeutics Inc. since October 2019. He has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since Septembe...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD7.76M) is above average for companies of similar size in the US market ($USD5.32M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ACAD's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ACAD's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

ACADIA Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ACADIA Pharmaceuticals Inc.
  • Ticker: ACAD
  • Exchange: NasdaqGS
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.410b
  • Shares outstanding: 160.18m
  • Website: https://www.acadia-pharm.com

Number of Employees


Location

  • ACADIA Pharmaceuticals Inc.
  • 12830 El Camino Real
  • Suite 400
  • San Diego
  • California
  • 92130
  • United States

Listings


Biography

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/27 02:12
End of Day Share Price2021/07/26 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.